Company attributes
Other attributes
Capricor Therapeutics is a biotechnology company that is interested in developing and commercializing cell and exosome-based therapeutics for the purpose of treating and preventing diseases. The company was founded in 2005 in Los Angeles, California, United States.
The company has developed an allogenic cell therapy that is meant to treat Duchenne muscular dystrophy as well as COVID-19. They have been developing extracellular vesicles and are researching potential exosome-based candidates for treating a variety of disorders.
Capricor Therapeutics' lead candidate for treatments is the CAP-1002. It works as a cardiac cell therapy that directly treats Duchenne muscular dystrophy and COVID-19. It consists of cardiosphere-derived cells (CDCs) and a population of cells that exert immunomodulatory activity to alter an immune system's activity, stimulating cellular regeneration.
The company investigates exosome science and biologically-active contents secreted by cells. They look to serve both direct and re-direct activities that serve other cells.
